Gapping down
In reaction to earnings/guidance:
- BASE -15.7%, SAM -9.3% (withdraws guidance; expects EPS to fall below prior guidance), ABM -9%, GME -8.3%, AVAV -7.6%, CVGW -4.6% (also CEO to retire), S -2.3%, JG -1.4%
Other news:
- HGEN -58% (FDA denies Emergency Use Authorization request for Lenzilumab)
- APLT -8.5% (reports initial biomarker data from the pediatric ACTION-Galactosemia Kids study)
- CERT -7.1% (prices offering of 4.5 mln shares of common stock at $31.00 per share)
- SKIN -5.5% (convertible notes offering)
- DLR -4.2% (prices offering of 6.25 mln shares of common stock at $160.50 per share)
- VICI -3.5% (stock offering; also files mixed securities shelf offering)
- BBCP -2.8% (acquires Hi-Tech Concrete Pumping Services)
- BIGC -2.5% (convertible notes offering)
- FTAI -2.4% (stock offering)
- TMUS -2.2% (indicated lower on block trade pricing)
- GEVO -2.2% (entered into an amendment to the At-The-Market Offering Agreement)
- SNY -1.6% (reports Phase 3 study of rilzabrutinib did not meet primary endpoint )
- TSN -0.9% (Categorically Rejects Conclusions Drawn by White House)
- UAL -0.8% (provides updates; has seen in the last few weeks a deceleration in customer bookings vs previous estimations due to the recent spike in COVID-19 cases associated with the Delta variant)
- LUV -0.7% (lowers Q3 operating revenue outlook)
Analyst comments:
- ES -2.1% (downgraded to Underperform from Neutral at Mizuho)
- AXTA -1.6% (downgraded to Neutral from Buy at Citigroup)
- CSCO -1% (downgraded to Equal-Weight from Overweight at Morgan Stanley)